Newest first
New topics page 27
Topics ordered by when they were created rather than by activity. This is where a question that nobody has answered yet is easiest to find — and answering one is the fastest route to a first solution badge.
1,535 topics · page 27 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Home & field testing category
What consumer-accessible tests can and cannot tell you. Mostly a subcategory about limitations. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
|
4 | 51k | 11mo | |
|
Journal club: SELECT, absolute risk, and how it was reported — a second dataset
On the subject in the title: Journal club: SELECT, absolute risk, and how it was reported — a second dataset Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SELECT ( N…
|
4 | 1.3k | 1mo | |
|
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?
Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Comparing STEP 2 ( Lancet , 2021) with…
|
+7 | 11 | 281 | 6mo |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…
|
+6 | 10 | 6.1k | 8mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI
Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…
|
+36 | 40 | 44k | 11mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…
|
+128 | 145 | 3k | 4mo |
|
How to read a phase 2 result without treating it as a phase 3 result — what changed since
Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…
|
+25 | 35 | 568 | 6mo |
|
Can a home kit substitute for a laboratory report? A careful no
Asking directly, because I could not find a straight answer: Can a home kit substitute for a laboratory report? A careful no I would like to understand what this number means before I repeat it anywhere. A…
|
+122 | 131 | 1.7k | 5mo |
|
About the Feature requests category
Requests for platform and documentation features, with the reasoning that justifies them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
4 | 28k | 9mo | |
|
The most useful thing you learned here that was not the answer you came for — a second dataset
Posting this under the heading it deserves: The most useful thing you learned here that was not the answer you came for — a second dataset Everything below is what sits behind that. Lower-stakes topic, but…
|
+111 | 121 | 6.6k | 9mo |
|
How to tell whether your question is already answered on a maintained page
How to tell whether your question is already answered on a maintained page — that is the question, and I have not found it answered plainly anywhere I have looked. Question in the title. Context below, and I…
|
+5 | 9 | 30k | 3mo |
|
Why most self-reports here are not experiments, and that is fine
Why most self-reports here are not experiments, and that is fine — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…
|
2 | 46k | 11mo | |
|
What published stability data actually covers, and what it does not — what changed since
What published stability data actually covers, and what it does not — what changed since — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question with the…
|
3 | 43k | 6mo | |
|
EU-wide position versus national implementation — what changed since
EU-wide position versus national implementation — what changed since Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included,…
|
+22 | 26 | 58k | 2mo |
|
Coming back to: Why most self-reports here are not experiments, and that is fine
The question in the title: Why most self-reports here are not experiments, and that is fine I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med , 2016) with…
|
+56 | 62 | 11k | 4mo |
|
The nausea timeline across the first four weeks, with a tabulated log
The nausea timeline across the first four weeks, with a tabulated log — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern…
|
+118 | 134 | 1.8k | 10mo |
|
Request: show the solution author in the topic list
Posting this under the heading it deserves: Request: show the solution author in the topic list Everything below is what sits behind that. Nominating something for promotion into the documentation commons.…
|
2 | 2.4k | 10mo | |
|
Oral semaglutide bioavailability and its variability between people
Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in…
|
+44 | 48 | 574 | 3mo |
|
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A coverage question with the paperwork detail…
|
+11 | 15 | 11k | 9mo |
|
[2026 update] Does dual agonism explain the effect size, or is it dose?
Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting; the…
|
+58 | 63 | 40k | 9mo |
|
Second pass at: LOD and LOQ: definitions people get wrong
Posting this under the heading it deserves: Second pass at: LOD and LOQ: definitions people get wrong Everything below is what sits behind that. Working through the identity arithmetic and I would like it…
|
+47 | 51 | 40k | 10mo |
|
Second pass at: The mass-error checker and its intended scope
Posting this under the heading it deserves: Second pass at: The mass-error checker and its intended scope Everything below is what sits behind that. Working through the identity arithmetic and I would like it…
|
+70 | 74 | 1.7k | 8mo |
|
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with STEP 4 ( JAMA , 2021) and…
|
+11 | 15 | 4k | 10mo |
|
A parcel that arrived warm: a decision process, not a verdict
A parcel that arrived warm: a decision process, not a verdict Writing it up because I had to work it out twice and would rather nobody else did. A question about technique rather than about dose. I have been…
|
+130 | 140 | 12k | 8mo |
|
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…
|
+45 | 49 | 15k | 8mo |
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…
|
+50 | 54 | 1.4k | 11mo |
|
[2026 update] Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 ( N Engl J Med , 2021) with…
|
+105 | 118 | 18k | 11mo |
|
Hypertension improvement and when medication needs revisiting
Hypertension improvement and when medication needs revisiting Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+74 | 79 | 1.1k | 10mo |
|
Particulates in a reconstituted solution: identifying the likely source
Posting this under the heading it deserves: Particulates in a reconstituted solution: identifying the likely source Everything below is what sits behind that. Posting the method first, because I know what the…
|
+15 | 19 | 13k | 9mo |
|
Enforcement priorities versus written rules — does this still hold?
Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Structured report rather than an opinion, following…
|
+36 | 40 | 37k | 11mo |